Contemporary Imaging in Early Phase Clinical Trials

Event Date:
Thursday 4th July - Breakfast Event 9am -11am (Doors Open 8.30)
Location:
Glaziers Hall, 9 Montague Cl, London SE1 9DD
View ProgramView Program

Richmond Pharmacology will be holding an event to show how the effective use of Contemporary Imaging and a pragmatic regulatory and commercial environment, combined with cutting edge innovative study designs can help you drive your early stage clinical programs forward and maximise information obtained, supporting optimised global development.The event will focus on Contemporary Imaging and how this can be effectively used in clinical research Learn more about a field which is constantly evolving as new technologies develop and institutes find new ways of using existing technologies, providing clinicians and research scientists with never-before-seen views inside the human body.The event provides the most up-to date research, data and developments that will enable better patient outcomes, efficiency and cost effectiveness in Global drug development.

Date, Time & Location

-Date: Thursday 4th JulyTime: Breakfast Event 9am -11am (Doors Open 8.30am)Location: Glaziers Hall, 9 Montague Cl, London SE1 9DD

The event will be followed by Q&A and a networking reception.

-

To Register for the Event

Limited space’s available.Please RSVP Jack Wilmott - j.wilmott@richmondpharmacology.com

First Speakers Confirmed

-Professor Steve Williams Professor Steve Williams is the founder and Head of Department of Neuroimaging at the Centre for Neuroimaging Sciences, based at the IoPPN and Maudsley Hospital, King’s College London. Steve has co-authored over 700 papers and chapters in leading neuroscience journals and has already achieved an h-index of >120 and more than 60,000 citations for his work.He graduated from Loughborough University in 1985 and spent a formative year working for Beecham Pharmaceuticals in Harlow before seeking the first ever PhD in Magnetic Resonance Imaging from the University of Cambridge.He went on to set up a University of London Intercollegiate Imaging facility which focused on the development and application of magnetic resonance techniques in a wide range of pre-clinicalmodels of disease. In the mid ’90s he then moved to the Institute of Psychiatry to champion the application of neuroimaging in a broad range of neurological and psychiatric disorders and, in 2014 he was elected a Fellow to the Academy of Medical Sciences in recognition of his scientific achievements.For the past decade Steve has aimed to make brain imaging an essential clinical tool in neuropsychiatry and continues to develop innovative imaging methods to measure structure, function, physiology and metabolism. He is extremely grateful for the wide range of funding which supports him and his department. These include the Wellcome Trust, NIHR, Medical Research Council, EPSRC and European Union as well as numerous industrial partners including GSK, GE Healthcare, Pfizer, Lilly, Roche, Eisai, Takeda and Janssen.Dr Amedeo Chiribiri MBBS PhD FHEA FSCMRAmedeo Chiribiri received his degree in Medicine from the University of Turin (Italy) with an experimental thesis on the role of coronary endothelium in the modulation of myocardial contractility in 2001. He completed his training in Cardiology in 2006 and received his PhD in Experimental Medicine and Human Physiology in 2011.After an experience as research fellow in human cardiovascular physiology the University of Turin, during his training in cardiology he has developed an interest in non-invasive cardiovascular imaging, in particular echocardiography, cardiac computed tomography and magnetic resonance imaging.He is currently researcher in Cardiovascular Imaging and Biomedical Engineering at King’s College London and Honorary Consultant Cardiologist at Guy’s and St Thomas’ NHS Trust Foundation (United Kingdom).He is author/co-author of more than 80 scientific papers that appear in some of the most relevant international peer-reviewed journals and several book chapters.His research is mainly focused on the non-invasive and high-resolution quantification of myocardial perfusion and assessment of coronary pathophysiology.Dr Haotian Gu PhD MSc (Biomed) MSc (Echo) CSci HSSHaotian Gu is a NIHR Clinical Lecturer and Higher Specialist Scientist in Cardiac Imaging based at Guy’s and St Thomas’ Hospitals and King’s College London.He received his first degree in Biomedical Engineering and Master degrees in Advanced Biomedical Engineering at University of Warwick and Medical Ultrasound at Imperial College London. He was awarded PhD degree in Cardiovascular Science at King’s College London. He started his clinical echocardiography training in 2007 and completed registration as a Clinical Scientist in 2017 and Higher Specialist Scientist in 2019.He was nominated for British Heart Foundation Rising Star Award in 2018 and awarded Investigator of the Year by British Society of Echocardiography consecutively in 2017 and 2018.During his academic career, he has invented a novel imaging biomarker of detection of early systolic dysfunction. His main research focus is on non-invasiveDr Jörg Täubel MD FFPM (CEO)Dr Jorg Taubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in clinical pharmacology for 24 years and during that time he has conducted more than 400 early phase studies in patients and healthy volunteers; usually in the capacity of Principal Investigator since 1995. His experience ranges from first time in man (FTIM) to proof of concept (POC) studies. He has extensive experience in cardiology, neurology, gastroenterology, ethnic bridging studies. His work currently focusses on providing expert advice in cardiac safety assessments and ethnic comparison studies. Dr Taubel is an honorary fellow at St George's University and author of over 50 publications in scientific journals. He is currently researching the role of hyperglycaemia in relation to sudden cardiac death in Type I diabetic patients. He presented his research at numerous international meetings and workshops in Europe, US and Japan.

Times and Additional Speakers TBC

-About the Historic VenueThe original Glaziers Hall in Fye Foot Lane was destroyed during the Great Fire of London in 1666 and was not relocated for another 300 years. Its current home, which was built in 1808, adjoins London Bridge and the so-called 'Nancy Steps' made famous by Charles Dickens' Oliver Twist. Today, Glaziers Hall is still home to three prestigious livery companies; The Worshipful Company of Glaziers, The Worshipful Company of Scientific Instrument Makers and The Worshipful Company of Launderers.Limited space’s available.Please RVSP Jack Wilmott - j.wilmott@richmondpharmacology.com

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more